JAK/TYK2

Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today. Rheumatoid Factor Lowering Predicts Improved Outcomes in RA. Abstract…

There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. Importantly, several drug approvals in lupus have occurred recently: belimumab (high dose) for lupus…

The pharmacology treatment in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. As we have…

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis (RA) due to the risk of cardiovascular (CV) events. These CV…